MEETINGS - Conference on Clarifying Adverse Event Reporting Responsibilities for Medical Devices and Borderline Products (UK) March 2000:
This article was originally published in Clinica
IIR will hold a conference on Clarifying Adverse Event Reporting Responsibilities for Medical Devices and Borderline Products in London on March 27-28. The meeting will include a keynote address from Joseph Putzeys of the European Commission on implementation of the medical device directives in Europe. There will also be regulatory updates from the UK, France, Germany, Hungary and Norway and practical industry case studies on successfully managing adverse event reporting for medical devices. IIR will also hold a workshop on Overcoming the Practical Challenges of Product Labelling for Medical Devices in London on March 29. For more information contact IIR in UK. Tel: +44 20 7915 5055. Fax: +44 171 915 5001.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.